Research Frontiers Incorporated logo

Research Frontiers IncorporatedNASDAQ: REFR

Profile

Sector:

Technology

Country:

United States

IPO:

08 July 1986

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$75.42 M
-20%vs. 3y high
28%vs. sector
-vs. 3y high
-vs. sector
-35%vs. 3y high
97%vs. sector
-58%vs. 3y high
98%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:02:27 GMT
$2.25+$0.05(+2.27%)

Dividend

No data over the past 3 years
$489.60 K-$94.00 K

Analysts recommendations

Institutional Ownership

REFR Latest News

RESEARCH FRONTIERS TO HOST THIRD QUARTER 2024 CONFERENCE CALL
globenewswire.com04 November 2024 Sentiment: -

WOODBURY, NY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq:  REFR ) announced today that it will release its third quarter 2024 financial results on Thursday, November 7, 2024. Research Frontiers will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 7, 2024 to discuss its third quarter 2024 financial and operating results, as well as recent developments.

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
globenewswire.com01 November 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-P1, the registration-directed study of luveltamab tazevibulin (luvelta) for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) acute myeloid leukemia (AML), has been initiated and is open for enrollment.

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
globenewswire.com22 August 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-L1, the global Phase 2 study of luveltamab tazevibulin (luvelta) for patients with non-small cell lung cancer (NSCLC) whose tumor expresses Folate Receptor-α (FRα), has been initiated and is open for enrollment. Initial data from this study is expected in the first half of 2025.

Research Frontiers, Inc. (REFR) Q2 2024 Earnings Call Transcript
seekingalpha.com02 August 2024 Sentiment: POSITIVE

Research Frontiers, Inc. (NASDAQ:REFR ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Joe Harary - President & CEO Conference Call Participants Neal Goldman - Goldman Capital Management Michael Kay - Kay Associates Leonard Lietzow - Private Investor Jeff Harvey - Private Investor Allen Ginsberg - Private Investor Operator Good afternoon ladies and gentlemen. Welcome to the Research Frontiers Investor Conference Call to discuss the Second Quarter of 2024 results of operations and recent developments.

Research Frontiers Reports Second Quarter 2024 Financial Results and Will Host a Conference Call at 4:30p.m. Today
globenewswire.com01 August 2024 Sentiment: NEUTRAL

WOODBURY, N.Y., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR ) announced its financial results for its second quarter of 2024. Management will host a conference call today at 4:30 p.m. Eastern Time to discuss its financial and operating results as well as recent developments.

RESEARCH FRONTIERS TO HOST SECOND QUARTER 2024 CONFERENCE CALL
globenewswire.com29 July 2024 Sentiment: POSITIVE

WOODBURY, NY, July 29, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq:  REFR ) announced today that it will release its second quarter 2024 financial results on Thursday, August 1, 2024. Research Frontiers will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 1, 2024 to discuss its second quarter 2024 financial and operating results, as well as recent developments.

Research Frontiers Incorporated (REFR) Q4 2023 Earnings Call Transcript
Seeking Alpha07 March 2024 Sentiment: POSITIVE

Research Frontiers Incorporated (NASDAQ:REFR ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Joe Harary – President and Chief Executive Officer Conference Call Participants Ted Campbell – Private Investor Alan Ginsberg – Private Investor Gerald Sherman – Strategic Planning Group Art Brady – Private Investor John Nelson – Private Investor August Berman – Private Investor Mike Zelnick – Private Investor Bruce Denny – Private Investor Jeff Harvey – Private Investor Seth Nickerson – Private Investor Operator Good afternoon, ladies and gentlemen. Welcome to Research Frontiers Investor Conference Call to discuss the Fourth Quarter and Full Year 2023 Results of operations and recent developments.

Research Frontiers Incorporated (REFR) Q2 2023 Earnings Call Transcript
Seeking Alpha06 August 2023 Sentiment: POSITIVE

Research Frontiers Incorporated (NASDAQ:REFR ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Joseph Harary - President and CEO Conference Call Participants Operator Good afternoon, ladies and gentlemen. Welcome to the Research Frontiers Investor Conference Call to discuss the Second Quarter of 2023 Results of Operations and recent developments.

Research Frontiers Incorporated (REFR) Q1 2023 Earnings Call Transcript
Seeking Alpha06 May 2023 Sentiment: POSITIVE

Research Frontiers Incorporated (NASDAQ:REFR ) Q1 2023 Results Conference Call May 4, 2023 4:30 PM ET Company Participants Joe Harary - President and CEO Conference Call Participants Jared Sherman - Strategic Planning Group Operator Good afternoon, ladies and gentlemen. Welcome to the Research Frontiers Investor Conference Call to discuss the first quarter of 2023 results of operations and recent developments.

What type of business is Research Frontiers Incorporated?

Research Frontiers Incorporated engages in the development and marketing of technology and devices to control the flow of light worldwide. It develops and licenses suspended particle device (SPD-Smart) light-control technology to companies that manufacture and market the SPD-Smart chemical emulsion, light-control film made from the chemical emulsion, the light-control panels made by laminating the film, and electronics to power end-products incorporating the film, as well as lamination services for and the end-products, such as windows, skylights, and sunroofs. The company's SPD-Smart light-control technology is used in various product applications, including windows, sunshades, skylights, and interior partitions for homes and buildings; automotive windows, sunroofs, sun-visors, sunshades, rear-view mirrors, instrument panels, and navigation systems; aircraft windows; museum display panels, and eyewear products; and flat panel displays for electronic products. It serves architectural, automotive, marine, and aerospace and appliance applications. The company was incorporated in 1965 and is headquartered in Woodbury, New York.

What sector is Research Frontiers Incorporated in?

Research Frontiers Incorporated is in the Technology sector

What industry is Research Frontiers Incorporated in?

Research Frontiers Incorporated is in the Electronic Components industry

What country is Research Frontiers Incorporated from?

Research Frontiers Incorporated is headquartered in United States

When did Research Frontiers Incorporated go public?

Research Frontiers Incorporated initial public offering (IPO) was on 08 July 1986

What is Research Frontiers Incorporated website?

https://www.smartglass.com

Is Research Frontiers Incorporated in the S&P 500?

No, Research Frontiers Incorporated is not included in the S&P 500 index

Is Research Frontiers Incorporated in the NASDAQ 100?

No, Research Frontiers Incorporated is not included in the NASDAQ 100 index

Is Research Frontiers Incorporated in the Dow Jones?

No, Research Frontiers Incorporated is not included in the Dow Jones index

When was Research Frontiers Incorporated the previous earnings report?

No data

When does Research Frontiers Incorporated earnings report?

Next earnings report date is not announced yet